IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

被引：0

作者：

Miller, M. ^{[1
]}

Sahin, U. ^{[2
]}

Derhovanessian, E. ^{[3
]}

Kloke, B-P. ^{[1
]}

Simon, P. ^{[4
]}

Bukur, V. ^{[5
]}

Albrecht, C. ^{[6
]}

Paruzynski, A. ^{[5
]}

Loewer, M. ^{[7
]}

Kuhn, A. ^{[8
]}

Schreeb, K. ^{[9
]}

Attig, S. ^{[10
]}

Brueck, A. Kemmer ^{[9
]}

Bolte, S. ^{[9
]}

Grabbe, S. ^{[11
]}

Hoeller, C. ^{[12
]}

Utikal, J. ^{[13
]}

Huber, C. ^{[14
]}

Loquai, C. ^{[11
]}

Tuereci, O. ^{[15
]}

机构：

[1] Biopharmaceut New Technol BioNTech Corp, Project Management, Mainz, Germany

[2] Biopharmaceut New Technol BioNTech Corp, Management, Mainz, Germany

[3] Biopharmaceut New Technol BioNTech Corp, Immunomonitoring, Mainz, Germany

[4] Biopharmaceut New Technol BioNTech Corp, Immunoreceptor Validat, Mainz, Germany

[5] Biopharmaceut New Technol BioNTech Corp, Genom, Mainz, Germany

[6] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Genom, Mainz, Germany

[7] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Bioinformat, Mainz, Germany

[8] Biopharmaceut New Technol BioNTech Corp, RNA Biochem, Mainz, Germany

[9] Biopharmaceut New Technol BioNTech Corp, Clin Res, Mainz, Germany

[10] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Immunmonitoring, Mainz, Germany

[11] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany

[12] Med Univ Vienna, Dermatol, Vienna, Austria

[13] German Canc Res Ctr, Dermatol, Heidelberg, Germany

[14] Biopharmaceut New Technol BioNTech Corp, Advisory Board, Mainz, Germany

[15] CI3 Cluster Individualized Immunointervent, Management, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[21] First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial
Streby, Keri A.
Currier, Mark A.
Triplet, Melinda
Ott, Kristy
Dishman, Devon J.
Vaughan, Michele R.
Ranalli, Mark A.
Setty, Bhuvana
Skeens, Micah A.
Whiteside, Stacy
Yeager, Nicholas D.
Haworth, Kellie B.
Simpson, Kathleen
Conner, Joe
Cripe, Timothy P.
MOLECULAR THERAPY, 2019, 27 (11) : 1930 - 1938
[22] Safety and efficacy of first-in-human intrathecal transplantation of human astrocytes (AstroRx®) in ALS patients: Phase I/IIA clinical trial results
Izrael, Michal
Gotkine, Marc
Slutsky, Guy
Lerner, Yossef
Chebath, Judith
Kuperstein, Graciela
Estrin, Elena
Caraco, Yoseph
Ben-Hur, Tamir
Hasson, Arik
Sonnefeld, Tehila
Stark, Yafit
Revel, Ariel
Revel, Michel
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 256 - 256
[23] Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials
Hansen, Aaron R.
Cook, Natalie
Ricci, M. Stacey
Razak, Albiruni
Le Tourneau, Christophe
McKeever, Kathleen
Roskos, Lorin
Dixit, Rakesh
Siu, Lillian L.
Hinrichs, Mary Jane
ONCOLOGIST, 2015, 20 (06): : 653 - 659
[24] First-in-human phase I trial of NHS-IL12 in advanced solid tumors
Kim, Joseph W.
Heery, Christopher Ryan
Bilusic, Marijo
Singh, Nishith K.
Madan, Ravi A.
Sabzevari, Helen
Schlom, Jeffrey
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[25] An Open-Label, First-in-Human, Phase I Trial of Daily Pclx-001
Sangha, Randeep
Mackey, John R.
Sehn, Laurie H.
Kuruvilla, John
Weickert, Michael J.
Berthiaume, Luc G.
BLOOD, 2021, 138
[26] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Hong, David S.
Kurzrock, Razelle
Supko, Jeffrey G.
He, Xiaoying
Naing, Aung
Wheler, Jennifer
Lawrence, Donald
Eder, Joseph Paul
Meyer, Colin J.
Ferguson, Deborah A.
Mier, James
Konopleva, Marina
Konoplev, Sergej
Andreeff, Michael
Kufe, Donald
Lazarus, Hillard
Shapiro, Geoffrey I.
Dezube, Bruce J.
CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3396 - 3406
[27] Choice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trials.
Hansen, Aaron Richard
Cook, Natalie
Ricci, M. Stacey
Razak, Albiruni R. A.
Le Tourneau, Christophe
McKeever, Kathleen
Roskos, Lorin
Dixit, Rakesh
Siu, Lillian L.
Hinrichs, Mary Jane
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[28] Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial
Kashihara, Tairo
Nakamura, Satoshi
Yamazaki, Naoya
Takahashi, Akira
Namikawa, Kenjiro
Ogata, Dai
Nakano, Eiji
Okuma, Kae
Kaneda, Tomoya
Mori, Taisuke
Ito, Kimiteru
Itami, Jun
Shimada, Kazuaki
Nakagama, Hitoshi
Igaki, Hiroshi
RADIOTHERAPY AND ONCOLOGY, 2025, 202
[29] A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001
Sangha, Randeep
Sehn, Laurie H.
Jamal, Rahima
Spratlin, Jennifer
Kuruvilla, John
Weickert, Michael J.
Berthiaume, Luc G.
Mackey, John R.
BLOOD, 2022, 140 : 12057 - 12058
[30] First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
Hernandez-Jimenez, Macarena
Martin-Vilchez, Samuel
Ochoa, Dolores
Mejia-Abril, Gina
Roman, Manuel
Camargo-Mamani, Paola
Luquero-Bueno, Sergio
Jilma, Bernd
Moro, Maria A.
Fernandez, Geronimo
Pineiro, David
Ribo, Marc
Gonzalez, Victor M.
Lizasoain, Ignacio
Abad-Santos, Francisco
MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 28 : 124 - 135

← 1 2 3 4 5 →